Short-term efficacy of abiraterone and docetaxel combined with prednisone in patients with metastatic castration-resistant prostate cancer and effects on serum indexes
Objective To analyze the short-term efficacy of abiraterone(ABI)and docetaxel(DOC)combined with prednisone in patients with metastatic castration-resistant prostate cancer(mCRPC)and the effects on disease-related serum indexes.Methods A total of 64 mCRPC patients admitted to the Second Affiliated Hospital of Wannan Medical College from January 2022 to April 2023 were selected as the study objects.They were divided into the experimental group and the control group by random number table method,with 32 cases each.The experimental group received ABI combined with prednisone,and the control group received DOC combined with prednisone.The short-term efficacy of the two groups after treatment was compared,the disease-related serum indexes and urodynamics indexes of the two groups before and after treatment were compared,and the occurrence of adverse reactions during treatment was compared between the two groups.Results After treatment,the short-term disease control rate of experimental group was higher than that of control group,and the difference was statistically significant(P＜0.05).Compared with before treatment,the levels of prostate-specific antigen(PSA),testosterone(T),cytokeratin 19 fragment(CYFRA21-1),residual urine volume and neurone-specific enolase(NSE)in both groups decreased after treatment,and the experimental group was lower than control group,with statistically significant differences(P＜0.05).Compared with before treatment,the maximum urine flow rate of both groups increased after treatment,and the experimental group was higher than control group,with statistically significant difference(P＜0.05).The adverse reactions during treatment of experimental group was lower than that in the control group,and the difference was statistically significant(P＜0.05).Conclusions ABI combined with prednisone has better short-term efficacy in mCRPC than DOC combined with prednisone,which could better regulate disease-related serum indexes,improve urodynamics and has better safety.
Metastatic castration-resistant prostate cancerAbirateroneDocetaxelPrednisoneShort-term efficacySerum index
万方数据
维普
